Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants
Public ClinicalTrials.gov record NCT01180790. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIa, Randomized, Double-blind (Participant and Investigator Blind, Sponsor Open), Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Antiviral Activity of Oral ACH-0141625 in Combination With Pegylated Interferon Alpha-2a and Ribavirin in Two Segments, After 28 Days of Dosing and, Subsequently, After 12 Weeks of Dosing in Participants With Chronic Hepatitis C Virus Genotype 1
Study identification
- NCT ID
- NCT01180790
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Enrollment
- 122 participants
Conditions and interventions
Conditions
Interventions
- ACH-0141625 (Sovaprevir) Drug
- Placebo Drug
- Pegylated Interferon alpha-2a Drug
- Ribavirin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2010
- Primary completion
- Feb 29, 2012
- Completion
- Mar 31, 2013
- Last update posted
- Aug 29, 2023
2010 – 2013
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Trial Site | Los Angeles | California | 90036 | — |
| Clinical Trial Site | Los Angeles | California | 90048 | — |
| Clinical Trial Site | San Francisco | California | 94115 | — |
| Clinical Trial Site | Bradenton | Florida | 34209 | — |
| Clinical Trial Site | Orlando | Florida | 32803 | — |
| Clinical Trial Site | Chicago | Illinois | 60611 | — |
| Clinical Trial Site | Overland Park | Kansas | 66211 | — |
| Clinical Trial Site | St Louis | Missouri | 63104 | — |
| Clinical Trial Site | Las Vegas | Nevada | 89106 | — |
| Clinical Trial Site | New York | New York | 10065 | — |
| Clinical Trial Site | Philadelphia | Pennsylvania | 19141 | — |
| Clinical Trial Site | Arlington | Texas | 76012 | — |
| Clinical Trial Site | San Antonio | Texas | 78215 | — |
| Clinical Trial Site | Newport News | Virginia | 23602 | — |
| Clinical Trial Site | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01180790, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 29, 2023 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01180790 live on ClinicalTrials.gov.